ORUM (475830.KQ) stock: key figures, P/E, revenue and dividend

Health Care · South Korea · ISIN KR7475830006

Price
14,990.00 KRW
Market cap
318.27 bn KRW
P/E (2025)
–
P/S (2025)
13,506.62
Dividend yield
0.00 %
Net margin
-178,105.42 %
Return on equity (ROE)
-32.06 %
Return on assets (ROA)
-24.79 %

ORUM financials

Fiscal year20242025
Revenue20.91 bn KRW23.56 m KRW
Gross profit20.91 bn KRW23.56 m KRW
Operating income-8.34 bn KRW-51.76 bn KRW
EBIT-3.52 bn KRW-42.27 bn KRW
Net income-5.74 bn KRW-41.97 bn KRW
Diluted EPS – continuing operations-274.27 KRW-1,976.66 KRW

Full history since 2022, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About ORUM

Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases in South Korea and the United States. The company develops ORM-6151, which is in Phase I clinical trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes; ORM-1153, which is in pre-clinical trial for the treatment of acute myeloid leukemia and hematologic malignancies; and ORM-1023, which is in pre-clinical trial for the treatment of small cell lung cancer and neuroendocrine tumor. It is also involved in the development of multiple programs for the treatment of solid tumors and immunology and inflammation; and E3 Ligase-DAC adaptor, an adaptor linker platform that conjugates protein degraders to antibodies and enables E3 ligase-based DACs. The company was founded in 2016 and is headquartered in Daejeon, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.